RxDoctor Payments Data

David Ko, MD

Internal Medicine · Rancho Mirage, CANPI 1568405470

Payments from drug & device makers

$21,488in general payments, 2019–2025

Across 37 payments — averaging $580.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$21K
  • Merck$142
  • AbbVie$125
  • Eisai Inc.$27
  • GSK$24

What the payments were for

  • Consulting fees$10,14747%
  • Speaking & faculty fees$8,15038%
  • Travel & lodging$1,5797%
  • Food & beverage$1,5857%
  • Education$270%

General payments by program year

20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Astellas Pharma US Inc32$21,169
Merck2$142
AbbVie1$125
Eisai Inc.1$27
GSK1$24

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,488 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$70,471
Medicare patients
279
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$148,326
OzempicSemaglutide47$58,228
JanuviaSitagliptin Phosphate17$22,207
EntrestoSacubitril/Valsartan13$19,163
JardianceEmpagliflozin11$18,004
XareltoRivaroxaban20$15,997
MyrbetriqMirabegron13$10,191
Spiriva HandihalerTiotropium Bromide14$7,871
Lagevrio (Eua)Molnupiravir12$6,057
TrintellixVortioxetine Hydrobromide12$5,727
Zolpidem Tartrate75$3,876
SynthroidLevothyroxine Sodium36$3,305
Celecoxib30$2,959
Levothyroxine Sodium218$2,941
Rosuvastatin Calcium129$2,407

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Lagevrio (Eua)$142$28,26429 claims
Astellas Pharma US IncMyrbetriq$21,169$10,19113 claims
AbbVieSynthroid$125$3,30536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rancho Mirage

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →